Intraductal Prostate Cancer: Any info about recurrence rates?

( sorry @jeffmarc, Imeant to reply to the OP)

There seem to be 2 types of IDC-P, pattern 1 and pattern 2.

One had a very similar prognosis (for the treatment given in the study) to normal PCa the other was more aggressive. The less aggressive variant was less common: 25-30%.
Can provide a link if you are interested.

I tried asking my urologist what type I have but he got no answer from the pathologist! I will ask for a second opinion from another pathologist.

I decided to add Abiraterone to my ADT because of the aggressive disease.

I am also cT3b N0M0 based on PET PSMA.

I also have quite a few studies I've collected but they are a bit depressing. 🙁

Just something to think about. If you are on Lupron or Orgovyx Or equivalent and it takes your PSA down to undetectable you may not want to start anything else. Because it can reduce the amount of time that you can stay undetectable or close to it.

I was able to go 2 1/2 years on Lupron before it failed and I became castrate resistant. I then started Zytiga And for 2 1/2 more years, it kept my cancer under control. The combination of drugs, so early may not be beneficial, It’s really hard to say

I’ve been on Darolutamide For almost a year and a half, and it’s kept my cancer undetectable. Getting 2 1/2 years out of Zytiga Was well worth it.

If your cancer has spread, and you have multiple metastasis, then maybe you want to use Triple therapy, which includes chemo.

I think things vary from person to person, but take a look at the STAMPEDE study. It seems to say that Abiraterone added to ADT earlier improved overall survival and metastasis free survival.

These people started off with a PSA with an average of 53.

I started on Zytiga, but not until after Lupron Failed, and Zytiga gave me 2.5 extra years after that. My PSA was 1.2 when I started Abbie.

The thing is drugs like Zytiga don’t work forever. I had to quit because it caused me heart issues. Other people I know have quit because it failed, and their PSA started rising.

Maybe taking it along with ADT could just be most beneficial when you have a high PSA, or when it is locally advanced or metastatic as the stampede trial says.

@michaelcharles hello
I hope you’re doing well
My father was recently diagnosed with intraductal prostate cancer stage 3C. And he doesn’t know if it better for him to go for a radical prostatectomy and radiation or just radiation!!! Please help us

@malvina
How old is he? If over (around) 75 then radiation would probably be better. Has he had a PSMA PET scan to see if the cancer has spread anywhere else in his body. That alone can make the decision because if it has spread than radiation is usually used.

It’s not very frequent that they recommend both surgery and radiation right away. After surgery, they always wanna wait a few months before they will do radiation.

Getting a decipher test might help decide what to do.

You don’t mention his Gleason score and that could be a big factor.

Is intraductal prostate cancer common?

@theocratic Generally, in overall prostate cancer population it is not very common 3 - 4 percent. However as you move up the Gleason scale or look at the population of people with more advanced cancer it is about 30-35%.

I was diagnosed at age 51 with intraductal PC. I was Gleason 4+3=7 with a tertiary score of 5. My PSA was only about 2.0 at the time.That was late 2017.

I had surgery in December 2017, then a recurrence after about 10 months. Then I had radiation to the prostate bed and two years of ADT. Once I got off it, and testosterone started to rise, my PSA did as well. Next, I had radiation to the abdomen region due to a reoccurrence in a lymph node. I did 18 months of ADT. Once my testosterone started to rise, it showed up on my hip bone. After that, my oncologist recommended that we hit it hard with six rounds of chemotherapy and going on Lupron and Nubeqa indefinitely. My last chemo infusion was October 2025.

I hope this helps. I wish you the very best of luck. Happy to talk more if helpful.